Show simple item record

dc.creatorPitteri, Sharon
dc.creatorHanash, Samir
dc.creatorAragaki, Aaron
dc.creatorAmon, Lynn
dc.creatorChen, Lin
dc.creatorBuson, Tina B.
dc.creatorPaczesny, Sophie
dc.creatorKatayama, Hiroyuki
dc.creatorWang, Hong
dc.creatorJohnson, Melissa
dc.creatorZhang, Qing
dc.creatorMcIntosh, Martin
dc.creatorWang, Pei
dc.creatorKooperberg, Charles
dc.creatorRossouw, Jacques
dc.creatorJackson, Rebecca
dc.creatorManson, JoAnn
dc.creatorHsia, Judith
dc.creatorLiu, Simin
dc.creatorMartin, Lisa
dc.creatorPrentice, Ross
dc.identifier.citationPitteri, Sharon, Hanash, Samir, Aragaki, Aaron, Amon, Lynn, Chen, Lin, Buson, Tina B., Paczesny, Sophie, Katayama, Hiroyuki, Wang, Hong, Johnson, Melissa, Zhang, Qing, McIntosh, Martin, Wang, Pei, Kooperberg, Charles, Rossouw, Jacques, Jackson, Rebecca, Manson, JoAnn, Hsia, Judith, Liu, Simin, Martin, Lisa, Prentice, Ross, "Postmenopausal estrogen and progestin effects on the serum proteome." Genome Medicine v1, n12 (December, 2009), pp. 121-en_US
dc.description.abstractBACKGROUND: Women's Health Initiative randomized trials of postmenopausal hormone therapy reported intervention effects on several clinical outcomes, with some important differences between estrogen alone and estrogen plus progestin. The biologic mechanisms underlying these effects, and these differences, have yet to be fully elucidated. METHODS: Baseline serum samples were compared with samples drawn 1 year later for 50 women assigned to active hormone therapy in both the estrogen-plus-progestin and estrogen-alone randomized trials, by applying an in-depth proteomic discovery platform to serum pools from 10 women per pool. RESULTS: In total, 378 proteins were quantified in two or more of the 10 pooled serum comparisons, by using strict identification criteria. Of these, 169 (44.7%) showed evidence (nominal P < 0.05) of change in concentration between baseline and 1 year for one or both of estrogen-plus-progestin and estrogen-alone groups. Quantitative changes were highly correlated between the two hormone-therapy preparations. A total of 98 proteins had false discovery rates < 0.05 for change with estrogen plus progestin, compared with 94 for estrogen alone. Of these, 84 had false discovery rates <0.05 for both preparations. The observed changes included multiple proteins relevant to coagulation, inflammation, immune response, metabolism, cell adhesion, growth factors, and osteogenesis. Evidence of differential changes also was noted between the hormone preparations, with the strongest evidence in growth factor and inflammation pathways. CONCLUSIONS: Serum proteomic analyses yielded a large number of proteins similarly affected by estrogen plus progestin and by estrogen alone and identified some proteins and pathways that appear to be differentially affected between the two hormone preparations; this may explain their distinct clinical effects.en_US
dc.description.sponsorshipFunding/Support: This work was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, U. S. Department of Health and Human Services [contracts HHSN268200764314C, N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-19, 32122, 42107-26, 42129-32, and 44221]. Clinical Trials Registration: identifier: NCT00000611. The work of Dr. Prentice was partially supported by grant CA53996 from the National Cancer Institute.en_US
dc.titlePostmenopausal estrogen and progestin effects on the serum proteomeen_US
dc.rights.ccAttribution 3.0 Unporteden_US

Files in this item


Items in Knowledge Bank are protected by copyright, with all rights reserved, unless otherwise indicated.

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 Unported
Except where otherwise noted, this item's license is described as Attribution 3.0 Unported